A randomized, double-blind, placebo-controlled trial on the drug treatment on sleep bruxism

A randomized, double-blind, placebo-controlled trial on the drug treatment on sleep bruxism - Effect of the drug on sleep bruxism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007805

Enrollment

Registered

2012-04-21

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Bruxism

Interventions

Clonazepam administration (1.0mg, 1-day, before sleep) (Wash out 2 weeks) Clonidine administration (0.15mg, 1-day, before sleep) (Wash out 2 weeks) Placebo administration (1-day, before

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with sleep bruxism

Exclusion criteria

Exclusion criteria: 1. Individual with cardiovascular disease 2. Individual with respiratory disease 3. Individual with digestive system disease 4. Individual with brain disease 5. pregnant, during the nursing, possibly pregnant and having the hope of child bearing. 6. Individual with medicine

Design outcomes

Primary

Measure	Time frame
1. Frequency of sleep bruxism episodes 2. Masticatory muscle activity during sleep 3. Frequency of tooth grinding noises	—

Secondary

Measure	Time frame
1. Sleep-stage distribution	—

Countries

Japan

Contacts

Public ContactBaba Kazuyoshi

Showa University School of Dentistry Department of Prosthodontics

kazuyoshi@dent.showa-u.ac.jp03-3787-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026